Mardaneh Jalal, Dallal Mohammad Mehdi Soltan
Department. of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran ; Prof. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department. of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran ; Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Microbiol. 2013 Sep;5(3):263-7.
Pantoea agglomerans is a Gram-negative rod in the Enterobacteriaceae family. It is reported as both commensal and opportunistic pathogen of animals and humans. This organism is potential candidates as powdered infant milk formula-borne opportunistic pathogen. The aim of our study was to perform isolation, identification and antimicrobial susceptibility pattern of Pantoea (Enterobacter) agglomerans strains isolated from consumed powdered infant formula milk (PIF) in NICU ward.
A of total 125 powdered infant formula milk (PIF) samples were purchased from hospital drug stores between June 2011 to March 2012. P. agglomerans was isolated according to FDA method. For final confirmation, biochemical tests embedded in the API-20E system were used. The drug susceptibility test was performed using the disc diffusion method according to CLSI guidelines.
Out of the 125 samples investigated, 8 (6.4%) samples were positive for P. agglomerans and these were uniformly susceptible to tigecycline, chloramphenicol, cefepime, levofloxacin, minocycline and colistin. Fifty percent of isolates were resistant to cefotaxime, moxifloxacin, cotrimoxazole and ticarcillin.
Controlling the primary populations of P. agglomerans during the PIF production process and preventing post processing contamination, by using suitable microbiological guidelines, is accessible. Sanitary practices for the preparation of infant formula in both the home and hospitals should be carefully controlled.
聚团泛菌是肠杆菌科的革兰氏阴性杆菌。据报道,它既是动物和人类的共生菌,也是机会致病菌。这种微生物有可能是婴幼儿配方奶粉中携带的机会致病菌。我们研究的目的是对从新生儿重症监护病房(NICU)食用的婴幼儿配方奶粉(PIF)中分离出的聚团泛菌(肠杆菌属)菌株进行分离、鉴定及抗菌药敏模式分析。
2011年6月至2012年3月期间,从医院药房购买了总共125份婴幼儿配方奶粉(PIF)样本。按照美国食品药品监督管理局(FDA)的方法分离聚团泛菌。为进行最终确认,采用了API - 20E系统中的生化试验。根据美国临床和实验室标准协会(CLSI)指南,使用纸片扩散法进行药敏试验。
在125份被调查的样本中,8份(6.4%)样本聚团泛菌检测呈阳性,这些菌株对替加环素、氯霉素、头孢吡肟、左氧氟沙星、米诺环素和黏菌素均敏感。50%的分离株对头孢噻肟、莫西沙星、复方新诺明和替卡西林耐药。
通过采用合适的微生物学指南,在婴幼儿配方奶粉生产过程中控制聚团泛菌的原始菌量并防止加工后污染是可行的。家庭和医院中婴幼儿配方奶粉制备的卫生操作都应得到严格控制。